| Activation of KRAS mediates resistance to targeted therapy in MET exon 14–mutant non–small cell lung cancer K Suzawa, M Offin, D Lu, C Kurzatkowski, M Vojnic, RS Smith, JK Sabari, ... Clinical Cancer Research 25 (4), 1248-1260, 2019 | 123 | 2019 |
| Epithelial tumor suppressor ELF3 is a lineage-specific amplified oncogene in lung adenocarcinoma KSS Enfield, EA Marshall, C Anderson, KW Ng, S Rahmati, Z Xu, M Fuller, ... Nature communications 10 (1), 5438, 2019 | 62 | 2019 |
| Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR-Mutated Lung Cancer K Suzawa, M Offin, AJ Schoenfeld, AJ Plodkowski, I Odintsov, D Lu, ... JCO precision oncology 3, 1-8, 2019 | 62 | 2019 |
| Integrative genomic analyses identifies GGA2 as a cooperative driver of EGFR-mediated lung tumorigenesis H O’Farrell, B Harbourne, Z Kurlawala, Y Inoue, AL Nagelberg, ... Journal of Thoracic Oncology 14 (4), 656-671, 2019 | 23 | 2019 |
| Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4 J Calder, A Nagelberg, J Luu, D Lu, WW Lockwood Oncogenesis 10 (3), 27, 2021 | 22 | 2021 |
| Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells FD Johnson, J Ferrarone, A Liu, C Brandstädter, R Munuganti, ... Cell reports 38 (6), 2022 | 19 | 2022 |
| MEK inhibitor resistance in lung adenocarcinoma is associated with addiction to sustained ERK suppression DA Farnsworth, Y Inoue, FD Johnson, G de Rappard-Yuswack, D Lu, ... NPJ Precision Oncology 6 (1), 88, 2022 | 14 | 2022 |
| MET exon 14 splice-site mutations preferentially activate KRAS signaling to drive Tumourigenesis D Lu, A Nagelberg, JLM Chow, YT Chen, Q Michalchuk, R Somwar, ... Cancers 14 (6), 1378, 2022 | 9 | 2022 |
| MEK inhibitor resistance in lung cancer cells associated with addiction to sustained ERK suppression DA Farnsworth, Y Inoue, FD Johnson, G de Rappard-Yuswack, D Lu, ... bioRxiv, 2022.04. 29.490009, 2022 | 2 | 2022 |
| Characterizing the secretome of EGFR mutant lung adenocarcinoma JK Luu, FD Johnson, J Jajarmi, T Sihota, R Shi, D Lu, D Farnsworth, ... Frontiers in Oncology 13, 1286821, 2024 | 1 | 2024 |
| A novel small molecule that induces cytotoxicity in lung cancer cells inhibits disulfide reductases GSR and TXNRD1 FD Johnson, J Ferrarone, A Liu, C Brandstädter, R Munuganti, ... bioRxiv, 2021.06. 28.450088, 2021 | 1 | 2021 |
| 2295P Pan-cancer prevalence of MET fusions and clinical response to MET-targeted therapy M Vojnic, I Odintsov, Z Liu, D Lu, M Harshan, A Ameri, S Machnicki, ... Annals of Oncology 34, S1175, 2023 | | 2023 |
| Anti-tumor activity of irreversible menin inhibitor, BMF-219, in high-grade B-cell lymphoma and multiple myeloma preclinical models P Somanath, D Lu, B Law, JT Palmer, T Kinoshita, M Balakrishnan, ... Cancer Research 82 (12_Supplement), 2654-2654, 2022 | | 2022 |
| B13 Selectively Targeting Lung Cancer with a Novel Small Molecule that Induces Lethality Through Dual Inhibition of Disulfide Reductases FD Johnson, S Jansen, A Liu, C Brandstädter, D Lu, A Nagelberg, ... Journal of Thoracic Oncology 15 (2), S31-S32, 2020 | | 2020 |
| P1. 02-073 Characterizing the Genomes of Lung Adenocarcinomas from Never Smokers Reveals SHPRH as a Novel Candidate Tumor Suppressor Gene: Topic: Other Mutations in Thoracic … T De Silva, V Martinez, K Thu, D Lu, M Oh, S Lam, W Lam, H Varmus, ... Journal of Thoracic Oncology 12 (1), S532-S533, 2017 | | 2017 |
